Erlotinib is a tyrosine kinase inhibitor used to treat non-small cell lung cancer and pancreatic cancer. It works by inhibiting the epidermal growth factor receptor (EGFR) pathway, that is involved in the growth and spread of cancer cells. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Tarceva and erlotinibum. Its PubChem CID is 176870.
Erlotinib
| CAS No | 183321-74-6 |
|---|---|
| Molecular Formula | C22H23N3O4 |
| Molecular Weight | 393.4 g/mol |
| Synonyms | N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Erlotinib is a tyrosine kinase inhibitor used to treat non-small cell lung cancer and pancreatic cancer. It works by inhibiting the epidermal growth factor receptor (EGFR) pathway, that is involved in the growth and spread of cancer cells.
The listed CAS number is 183321-74-6.
The listed molecular formula is C22H23N3O4.
The listed molecular weight is 393.4 g/mol.
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine.
The source lists Tarceva and erlotinibum.